Experience of using prolgolimab in real clinical practice
- Authors: Protsenko S.A1, Imyanitov E.N1,2, Malygin A.Y.1, Yurlov D.O1, Semenova A.I1, Latipova D.K.1, Novik A.V1,2, Teletaeva G.M1, Zinoviev G.V1, Ebert M.A1,2, Artemieva A.S1, Baldueva I.A1
-
Affiliations:
- N.N. Petrov National Medical Research Center of Oncology
- Saint Petersburg State Pediatric Medical University
- Issue: Vol 28, No 7 (2021)
- Pages: 51-55
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313178
- DOI: https://doi.org/10.18565/pharmateca.2021.7.51-55
- ID: 313178
Cite item
Abstract
Full Text
About the authors
S. A Protsenko
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
E. N Imyanitov
N.N. Petrov National Medical Research Center of Oncology; Saint Petersburg State Pediatric Medical UniversitySt. Petersburg, Russia
A. Yu Malygin
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
D. O Yurlov
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
A. I Semenova
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
D. Kh Latipova
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
A. V Novik
N.N. Petrov National Medical Research Center of Oncology; Saint Petersburg State Pediatric Medical UniversitySt. Petersburg, Russia
G. M Teletaeva
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
G. V Zinoviev
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
M. A Ebert
N.N. Petrov National Medical Research Center of Oncology; Saint Petersburg State Pediatric Medical UniversitySt. Petersburg, Russia
A. S Artemieva
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
I. A Baldueva
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
References
- Tjulandin S., Fedyanin M., Semiglazova T., et al. BCD-100 - first Russian PD-1 inhibitor. J Mod Oncol. 2017;19:13-20.
- Tjulandin S., et al. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice. Eur J Cancer. 2021;149:222-32. doi: 10.1016/j.ejca.2021.02.030.
- Rozeman E.A., et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med. 2021; 27(2):256-63. doi: 10.1038/s41591-020- 01211-7
- Blank C.U., Reijers I.L.M., Pennington T., et al. First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. J Clin Oncol. 2020;38;15S. URL: https://meetinglibrary.asco.org/record/185836/ abstract
- Krishnamoorthy M., Lenehan J.G., Vareki S.M. Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges, JNCI: J Nation Cancer Inst. 2021, djaa216. doi: 10.1093/jnci/djaa216. 7-y
- Huang A.C., et al.Asingledose ofneoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 2019;25(3):454-61. doi: 10.1038/s41591-019-0357-y